A Prospective Study of DT56a (Femarelle®) for the Treatment of Postmenopausal Vaginal Atrophy
Abstract Book, 22nd Annual Meeting of the North American Menopause Society, Sept. 21-24, 2011.; pg. 55.
DT56a (Femarelle®): a Natural Selective Estrogen Receptor Modulator (SERM)
Journal of Steroid Biochemistry and Molecular Biology 2007; 104:252-258
Pharmacological Doses of the Natural Phyto-SERM DT56a (Femarelle®) Have No Effect on MCF-7 Human Breast Cancer Cell-Line
European Journal of Obstetrics & Gynecology and Reproductive Biology
2007;130(1): 140-141
DT56a (Femarelle®) Stimulates Gender-Specific Human Cultured Bone Cells In Vitro
Journal of Steroid Biochemistry & Molecular Biology 2006;98(1):90-96
DT56a (Femarelle®/Tofupill) Stimulates Bone Formation in Female Rats
British Journal of Obstetrics & Gynecology 2005; 112(7):981-985
Efficacy and Safety of Standard versus Low Dose of Femarelle® (Tofupill) for the Treatment of Menopausal Symptoms
Journal of Clinical & Experimental Obstetrics & Gynecology 2004; 31(2): 123-126
DT56a Stimulates Creatine Kinase Specific Activity in Vascular Tissues of Rats
Journal of Endocrinological Investigation 2003;26(10):966-971
Efficacy and safety of DT56a compared to hormone therapy in Greek post-menopausal women.
J Endocrinol Invest. 2013 Jul-Aug;36(7):521-6. doi: 10.3275/8926. Epub 2013 Apr 8.
The pros and cons of plant estrogens for menopause
Journal of Steroid Biochemistry & Molecular Biology xxx (2013) xxx–xxx
Home   |   About   |   R&D   |   Pipeline   |   Media   |   Investors   |   Contact